Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
Year: 2022
Type: article
Source: Blood
Authors: Jane F. Apperley, Jorge E. Cortes, Elias Jabbour, Andreas Hochhaus, Timothy Hughes, Charles Chuah, Hugues de Lavallade, Michael W. Deininger, Jeffrey H. Lipton, Elza Lomaia, Lori Maness, Michael Mauro, James McCloskey, Beatriz Moiraghi, Carolina Pavlovsky, Christine Rojas, Philippe Rousselot, Tomasz Sacha, Moshe Talpaz, Anna Turkina, Maria Undurraga Sutton, Xiaowei Ren, Alexander Vorog, Gianantonio Rosti
Institutions: Imperial College London, The University of Texas MD Anderson Cancer Center, Jena University Hospital, The University of Adelaide, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, King's College Hospital, Versiti Blood Center of Wisconsin, Princess Margaret Cancer Centre, Federal Almazov North-West Medical Research Centre, Nebraska Medical Center, University of Nebraska Medical Center, Hackensack University Medical Center, Hospital Ramos Mejía, Université de Versailles Saint-Quentin-en-Yvelines, University of Michigan, National Medical Research Center for Hematology, Hospital del Salvador, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310127455